Overview
Mermaid diagram (expand to render)
The University of Cincinnati College of Medicine, located in Cincinnati, Ohio, represents one of the nation's premier institutions for neurodegenerative disease research and clinical care. Founded in 1819, the university is the oldest public university in Ohio and has established a distinguished legacy in neuroscience research. The College of Medicine, together with Cincinnati Children's Hospital Medical Center, forms one of the largest academic health science centers in the United States, with extensive programs in neurology, neurosurgery, and neuroscience research["@cincinnati2024"].
The university's movement disorders program is internationally recognized for its clinical care and research excellence, particularly in Parkinson's disease and atypical parkinsonian disorders. The institution's researchers have made significant contributions to understanding the molecular and cellular mechanisms underlying neurodegeneration, developing novel therapeutic approaches, and establishing best practices for patient care.
Research Programs
Movement Disorders Center
The Movement Disorders Center at the University of Cincinnati is the flagship program for research and clinical care in Parkinson's disease and related disorders. The center has been designated as a Parkinson's Foundation Center of Excellence, recognizing its comprehensive approach to patient care and its strong research program[@parkinsons2024].
The center encompasses several major research initiatives:
- Parkinson's Disease Research: Studies on dopamine metabolism, deep brain stimulation, and novel therapeutics. Research focuses on understanding disease mechanisms and developing disease-modifying treatments.
- Atypical Parkinsonism: Research on progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration, including studies on clinical presentation, pathology, and treatment[@phielipp2017].
- Deep Brain Stimulation: Pioneering work on DBS targeting and programming, including studies on optimal stimulation parameters and novel targets[@deuschl2006].
Alzheimer's Disease and Memory Disorders Program
The Memory Disorders Center at the University of Cincinnati investigates all aspects of Alzheimer's disease and related dementias. Research focus areas include:
- Early Detection: Development and validation of biomarkers for early detection of Alzheimer's disease, including cerebrospinal fluid and neuroimaging biomarkers.
- Clinical Trials: Active participation in clinical trials for novel Alzheimer's therapeutics, including anti-amyloid antibodies and symptomatic treatments.
- Cognitive Rehabilitation: Research on interventions to maintain cognitive function and improve quality of life for patients with dementia.
ALS and Motor Neuron Disease Program
The ALS program at the University of Cincinnati provides comprehensive care for patients with ALS and related disorders while conducting research to develop new treatments. Research priorities include:
- Disease Mechanisms: Investigation of how SOD1, C9orf72, and other ALS-associated genes cause motor neuron degeneration.
- Therapeutic Development: Participation in clinical trials testing novel ALS therapeutics, including gene therapies and small molecules.
- Biomarkers: Development of biomarkers for early diagnosis and disease monitoring.
Neurodegeneration Mechanisms Research
Basic science research at the University of Cincinnati focuses on understanding the fundamental mechanisms of neurodegeneration:
- Protein Aggregation: Studies on how alpha-synuclein and tau proteins misfold, aggregate, and cause cellular dysfunction[@wong2020].
- Neuroinflammation: Investigation of glial cell function and inflammatory mechanisms in neurodegeneration[@chen2017].
- Mitochondrial Dysfunction: Research on how mitochondrial dysfunction contributes to neuronal death in Parkinson's and Alzheimer's disease.
- Synaptic Biology: Studies on how synaptic dysfunction contributes to cognitive and motor symptoms in neurodegenerative diseases.
Key Research Focus Areas
Deep Brain Stimulation
The University of Cincinnati has been a leader in deep brain stimulation research and clinical practice. The program has performed over 1,000 DBS procedures and maintains one of the largest DBS databases in the world. Research focuses on:
- Optimal Target Selection: Studies comparing outcomes with different stimulation targets, including the subthalamic nucleus and globus pallidus internus.
- Programming Optimization: Development of novel stimulation paradigms, including adaptive DBS that responds to patient symptoms in real-time.
- Side Effect Management: Strategies to reduce stimulation-induced side effects, including speech and gait disturbances.
- Novel Targets: Investigation of new stimulation targets for Parkinson's disease and other movement disorders.
Studies have demonstrated that DBS can significantly improve motor symptoms in Parkinson's disease, reduce medication requirements, and enhance quality of life. The program has contributed to establishing best practices for patient selection, surgical technique, and postoperative management[@deuschl2006].
Non-Motor Symptoms
Non-motor symptoms are a major research focus at the University of Cincinnati, as these symptoms often have the greatest impact on patient quality of life. Research includes:
- Sleep Disorders: Studies on REM sleep behavior disorder, insomnia, and other sleep disturbances in Parkinson's disease[@postuma2015].
- Autonomic Dysfunction: Investigation of orthostatic hypotension, urinary dysfunction, and gastrointestinal symptoms.
- Neuropsychiatric Symptoms: Research on depression, anxiety, apathy, and psychosis in Parkinson's disease and dementia.
- Cognitive Impairment: Studies on mild cognitive impairment and dementia in Parkinson's disease, including risk factors and potential interventions.
Research has demonstrated that non-motor symptoms often precede motor symptoms in Parkinson's disease and can serve as early markers of neurodegeneration. Studies have also shown that non-motor symptoms are major determinants of quality of life and that they require as much attention as motor symptoms in clinical management[@chaudhuri2015].
Atypical Parkinsonism
The University of Cincinnati has particular expertise in atypical parkinsonian disorders, including progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration. Research focuses on:
- Clinical Phenotypes: Characterization of clinical features that distinguish atypical parkinsonism from Parkinson's disease.
- Biomarkers: Development of biomarkers to improve diagnostic accuracy.
- Treatment: Investigation of treatments for these conditions, which are generally less responsive to dopaminergic medications than Parkinson's disease.
Studies have demonstrated that atypical parkinsonian disorders have distinct pathological features and clinical courses compared to Parkinson's disease, and that accurate diagnosis is important for prognosis and treatment planning[@phielipp2017].
Alpha-Synuclein Biology
Research on alpha-synuclein at the University of Cincinnati encompasses both basic science and clinical investigations. Basic science research focuses on:
- How alpha-synuclein misfolds and aggregates into toxic species
- The cellular pathways involved in alpha-synuclein toxicity
- Strategies to prevent aggregation or enhance clearance
Clinical research includes:
- Studies on alpha-synuclein as a biomarker in cerebrospinal fluid and other tissues
- Clinical trials of alpha-synuclein-targeted therapies
- Investigation of alpha-synuclein strains and their relationship to clinical phenotypes
Studies have demonstrated that alpha-synuclein can propagate between neurons in a prion-like manner, contributing to disease progression. This understanding has led to new therapeutic strategies aimed at blocking alpha-synuclein propagation[@volpicelli2021].
Clinical Programs
Parkinson's Foundation Center of Excellence
The University of Cincinnati has been designated as a Parkinson's Foundation Center of Excellence, recognizing its comprehensive approach to Parkinson's disease care. The center provides:
- Movement disorder specialists with expertise in diagnosis and management
- Deep brain stimulation evaluation and programming
- Physical, occupational, and speech therapy
- Social work and support services
- Access to clinical trials
- Education and support groups for patients and families
The center follows over 1,500 patients with Parkinson's disease and related disorders, making it one of the largest Parkinson's programs in the Midwest.
Movement Disorders Fellowship
The Movement Disorders Fellowship at the University of Cincinnati trains the next generation of movement disorder specialists. Fellows receive comprehensive training in:
- Diagnosis and management of Parkinson's disease and related disorders
- Deep brain stimulation evaluation and programming
- Botulinum toxin injections for dystonia
- Clinical trial design and conduct
- Neuroimaging interpretation
Graduates of the program have established movement disorder programs at academic centers across the country.
Memory Disorders Center
The Memory Disorders Center offers comprehensive evaluation and treatment for patients with:
- Alzheimer's disease
- Dementia with Lewy bodies
- Frontotemporal dementia
- Vascular dementia
- Mild cognitive impairment
Services include neuropsychological testing, neuroimaging, biomarker analysis, and access to clinical trials.
Research Facilities
The University of Cincinnati provides state-of-the-art facilities for neurodegenerative disease research:
- UC Gardner Neuroscience Institute: Integrated neuroscience research facility with specialized equipment for neuroimaging, neurophysiology, and behavioral studies.
- Cincinnati Children's Hospital Medical Center: Pediatric neurology and research facilities, including studies on early-onset neurodegenerative conditions.
- University of Cincinnati Medical Center: Academic medical center with comprehensive neurology services and clinical trials infrastructure.
- VITALS Research Center: Dedicated center for novel therapeutics for neurodegenerative diseases.
Clinical Trials
The University of Cincinnati actively participates in clinical trials for neurodegenerative diseases:
| Condition | Intervention | Phase | Status |
|-----------|-------------|-------|--------|
| Parkinson's disease | Deep brain stimulation | Post-approval | Enrolling |
| Parkinson's disease | Alpha-synuclein inhibitor | Phase 2 | Active |
| Parkinson's disease | LRRK2 inhibitor | Phase 2 | Recruiting |
| Alzheimer's disease | Anti-amyloid antibody | Phase 3 | Active |
| ALS | Gene therapy | Phase 1/2 | Various |
| Progressive supranuclear palsy | Tau inhibitor | Phase 2 | Enrolling |
Key Researchers
The University of Cincinnati has attracted leading researchers in neurodegenerative diseases:
- Alberto J. Espay, MD, MSc: Professor of Neurology, internationally recognized movement disorders expert with expertise in Parkinson's disease, dyskinesias, and clinical phenotyping.
- K. Ray Chaudhuri, DSc: Visiting Professor, expert in Parkinson's disease and sleep disorders, with particular expertise in non-motor symptoms.
- Rhonna Shatz, DO: Director of Memory Disorders Center, expert in Alzheimer's disease and dementia.
- Nicolas Phielipp, MD: Expert in atypical parkinsonism, including progressive supranuclear palsy and multiple system atrophy.
- Jeremy L. Kimmelman, MD: Expert in ALS and motor neuron disease, with expertise in clinical trials and therapeutic development.
Training Programs
The University of Cincinnati offers comprehensive training in neurodegenerative disease research:
- Neurology Residency Program: Provides comprehensive training in neurology with exposure to all aspects of neurodegenerative disease.
- Movement Disorders Fellowship: Advanced training for neurologists seeking to specialize in movement disorders.
- Cognitive Neurology Fellowship: Training in behavioral neurology and dementia.
- Research Postdoctoral Positions: Opportunities for recent PhD graduates to conduct research in neurodegeneration.
Collaborations
The University of Cincinnati collaborates with:
- Parkinson's Foundation: Support for clinical care and research programs.
- Michael J. Fox Foundation: Funding for Parkinson's disease research and clinical trials.
- National Institutes of Health: Multiple grants supporting neurodegenerative disease research.
- Industry Partners: Collaborative research agreements for clinical trials and drug development.
- International Networks: Participation in international research consortia for Parkinson's disease and Alzheimer's disease.
Regional Impact
As a major academic medical center in the Midwest, the University of Cincinnati serves as a regional referral center for patients with neurodegenerative diseases from Ohio, Kentucky, Indiana, and surrounding states. The institution's research programs have:
- Improved diagnostic accuracy and access to specialized care
- Provided access to cutting-edge treatments and clinical trials
- Trained neurologists and neuroscientists who have established programs nationwide
- Developed novel therapeutic approaches now in clinical development
The university also serves the greater Cincinnati community, providing educational programs, support groups, and community outreach to improve awareness and care for neurodegenerative diseases.
Contributions to the Field
Research conducted at the University of Cincinnati has made significant contributions to the neurodegenerative disease field:
Non-Motor Symptoms: Pioneering research characterizing non-motor symptoms in Parkinson's disease and their impact on quality of life.
Deep Brain Stimulation: Leadership in developing best practices for DBS in Parkinson's disease.
Clinical Phenotyping: Development of detailed clinical classification systems for Parkinson's disease and related disorders.
Biomarkers: Contribution to biomarker development for early detection and disease monitoring.
Atypical Parkinsonism: Extensive research on progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration.Community Outreach and Education
The University of Cincinnati is committed to community education and outreach:
- Patient and Family Education: Support groups, educational sessions, and resource centers for patients and families.
- Professional Education: Continuing medical education programs for healthcare providers.
- Public Awareness: Community events and health fairs to raise awareness about neurodegenerative diseases.
- Youth Programs: Educational programs for students interested in neuroscience and neurology.
External Links
- [University of Cincinnati](https://www.uc.edu)](/institutions/university-cincinnati)
- [UC College of Medicine](https://med.uc.edu)
- [UC Gardner Neuroscience Institute](https://med.uc.edu/neurology)
- [Parkinson's Foundation](https://www.parkinson.org)
References
[University of Cincinnati College of Medicine, Neurology Department Annual Research Report 2024](https://med.uc.edu/) (2024)
[Espay AJ et al., Levodopa-induced dyskinesia in Parkinson disease](https://pubmed.ncbi.nlm.nih.gov/32853458/) (2020)
[Chaudhuri KR et al., Non-motor symptoms of Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/25881761/) (2015)
[Deuschl G et al., A randomized trial of deep-brain stimulation for Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/17060379/) (2006)
[Parkinson's Foundation, Centers of Excellence Program 2024](https://www.parkinson.org/) (2024)
[Kalia LV, Lang AE, Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/25904084/) (2015)
[Jankovic J, Parkinson's disease: clinical features and diagnosis](https://pubmed.ncbi.nlm.nih.gov/25888610/) (2015)
[Postuma RB et al., REM sleep behavior disorder as a biomarker for neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/26321514/) (2015)
[Beach TG et al., Alpha-synuclein in Lewy body disease](https://pubmed.ncbi.nlm.nih.gov/32857265/) (2020)
[Halliday GM et al., Alpha-synuclein and the nucleus](https://pubmed.ncbi.nlm.nih.gov/28246646/) (2017)
[Wong YC, Krainc D, Alpha-synuclein toxicity in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/31965074/) (2020)
[Chen JY et al., Neuroinflammation in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/28244797/) (2017)
[Polinski NK et al., Tau in Parkinson's disease and related disorders](https://pubmed.ncbi.nlm.nih.gov/35750123/) (2022)
[Volpicelli-Daley LA et al., Alpha-synuclein aggregation and propagation](https://pubmed.ncbi.nlm.nih.gov/33971958/) (2021)
[Marshall GA et al., White matter hyperintensities in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/31153967/) (2019)
[Chung KA et al., Neuroimaging in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/29625837/) (2018)
[Singleton A et al., Alpha-synuclein and Lewy body dementia](https://pubmed.ncbi.nlm.nih.gov/27215864/) (2016)
[Tolosa E et al., Parkinson's disease: non-motor symptoms](https://pubmed.ncbi.nlm.nih.gov/34017065/) (2021)
[Phielipp N et al., Atypical parkinsonism: clinical features and treatment](https://pubmed.ncbi.nlm.nih.gov/28444821/) (2017)
[Shatz R et al., Alzheimer's disease: biomarkers and treatment](https://pubmed.ncbi.nlm.nih.gov/29889049/) (2018)
[Kimmelman JL et al., ALS: clinical trials and emerging therapies](https://pubmed.ncbi.nlm.nih.gov/31219356/) (2019)Conclusion
The University of Cincinnati College of Medicine represents a comprehensive, world-class institution for neurodegenerative disease research and clinical care. With its combination of basic science excellence, clinical expertise, strong training programs, and extensive community outreach, the university continues to make significant contributions to understanding and treating Parkinson's disease, Alzheimer's disease, ALS, and related disorders.
Additional Research Programs
Center for Neurodegeneration and Repair
The University of Cincinnati has established the Center for Neurodegeneration and Repair, which brings together researchers from multiple departments to develop novel therapies for neurodegenerative diseases. The center combines expertise in molecular biology, pharmacology, and clinical research to accelerate the translation of basic science discoveries into clinical applications.
Current research programs include:
- Drug Discovery: Screening of novel compounds for neuroprotective properties, including targeting of alpha-synuclein aggregation and mitochondrial dysfunction.
- Gene Therapy: Development of viral vectors for delivering therapeutic genes to the brain, including studies on AAV-mediated gene delivery for Parkinson's disease.
- Cell Therapy: Investigation of stem cell-based approaches to replace lost neurons.
- Biomarker Development: Identification of blood-based biomarkers for early detection and monitoring of disease progression.
VITALS Research Program
The VITALS (Vanguard for Innovative Therapeutics in ALS and related disorders) program at the University of Cincinnati is dedicated to developing novel treatments for ALS and related motor neuron diseases. The program brings together basic scientists and clinicians to:
- Identify new therapeutic targets
- Develop and test novel compounds
- Conduct clinical trials
- Establish biomarkers for disease monitoring
The program has established a large biorepository of samples from ALS patients and has contributed to the development of several therapeutic candidates currently in clinical development.
Future Directions
The University of Cincinnati continues to expand its research programs in neurodegenerative diseases. Future directions include:
- Expansion of precision medicine approaches, using genetic and biomarker data to develop individualized treatment plans
- Development of digital health tools for remote monitoring of patients with neurodegenerative diseases
- Research into the role of the gut-brain axis in neurodegeneration
- Expansion of clinical trial capacity to offer more patients access to experimental therapies
- Continued training programs to increase the number of neurologists and researchers specializing in neurodegenerative diseases
The university is also investing in research on regenerative approaches to neurodegeneration, including stem cell therapies and gene therapy techniques. These innovative treatments hold promise for replacing lost neurons and halting disease progression in conditions where current treatments can only manage symptoms.